239 related articles for article (PubMed ID: 19653732)
21. Epithelioid lesions of the serosa.
Anttila S
Arch Pathol Lab Med; 2012 Mar; 136(3):241-52. PubMed ID: 22372900
[TBL] [Abstract][Full Text] [Related]
22. Pathohistological diagnosis and differential diagnosis.
Tischoff I; Neid M; Neumann V; Tannapfel A
Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
[TBL] [Abstract][Full Text] [Related]
23. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
[TBL] [Abstract][Full Text] [Related]
24. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
25. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
[TBL] [Abstract][Full Text] [Related]
26. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F;
Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715
[TBL] [Abstract][Full Text] [Related]
27. Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features.
Taşkın S; Gümüş Y; Kiremitçi S; Kahraman K; Sertçelik A; Ortaç F
Int J Clin Exp Pathol; 2012; 5(5):472-8. PubMed ID: 22808303
[TBL] [Abstract][Full Text] [Related]
28. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
Manur R; Lamzabi I
Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731
[TBL] [Abstract][Full Text] [Related]
29. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
31. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
32. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
Betta PG; Magnani C; Bensi T; Trincheri NF; Orecchia S
Arch Pathol Lab Med; 2012 Mar; 136(3):253-61. PubMed ID: 22372901
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
[TBL] [Abstract][Full Text] [Related]
35. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
36. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
37. Podoplanin as a marker for mesothelioma.
Kimura N; Kimura I
Pathol Int; 2005 Feb; 55(2):83-6. PubMed ID: 15693854
[TBL] [Abstract][Full Text] [Related]
38. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
Leers MP; Aarts MM; Theunissen PH
Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
[TBL] [Abstract][Full Text] [Related]
39. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
40. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]